135 related articles for article (PubMed ID: 27936527)
1. Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.
Mazhar F; Ahmed Y
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):169-170. PubMed ID: 27936527
[No Abstract] [Full Text] [Related]
2. Enoxaparin dosing after cesarean delivery in morbidly obese women.
Overcash RT; Somers AT; LaCoursiere DY
Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Stephenson ML; Serra AE; Neeper JM; Caballero DC; McNulty J
J Perinatol; 2016 Feb; 36(2):95-9. PubMed ID: 26658126
[TBL] [Abstract][Full Text] [Related]
6. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
Freeman A; Horner T; Pendleton RC; Rondina MT
Am J Hematol; 2012 Jul; 87(7):740-3. PubMed ID: 22565589
[TBL] [Abstract][Full Text] [Related]
7. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
8. Assessing an enoxaparin dosing protocol in morbidly obese patients.
Lalama JT; Feeney ME; Vandiver JW; Beavers KD; Walter LN; McClintic JR
J Thromb Thrombolysis; 2015 May; 39(4):516-21. PubMed ID: 25087072
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
van Oosterom N; Winckel K; Barras M
J Thromb Thrombolysis; 2019 Oct; 48(3):387-393. PubMed ID: 30945098
[TBL] [Abstract][Full Text] [Related]
11. [Enoxaparin dosage in extreme obesity by monitoring anti-Xa factor].
Andújar Mateos A; Matoses Chirivella C; Rodríguez Lucena FJ; Navarro Ruiz A
Farm Hosp; 2016 Jan; 40(1):58-9. PubMed ID: 26882836
[No Abstract] [Full Text] [Related]
12. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report.
Than H; Loh JB; Sum CL; Ng HJ
J Clin Pathol; 2015 Apr; 68(4):318-9. PubMed ID: 25688138
[No Abstract] [Full Text] [Related]
13. Capillary blood samples for anti-Xa monitoring of heparin in paediatric patients.
Ridsdale S; Martin V; Payne JH
Thromb Haemost; 2017 Jan; 117(1):198-200. PubMed ID: 27761575
[No Abstract] [Full Text] [Related]
14. Treatment of suspected pulmonary embolism in a morbidly obese patient.
Heitlage V; Borgstadt MB; Carlson L
Am J Health Syst Pharm; 2017 Jul; 74(13):977-980. PubMed ID: 28645996
[TBL] [Abstract][Full Text] [Related]
15. Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
Rahawi KW; Higgins KL; Noda C; Stultz JS
Pharmacotherapy; 2017 Apr; 37(4):e16-e20. PubMed ID: 28152224
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients.
Tellor KB; Nguyen SN; Bultas AC; Armbruster AL; Greenwald NA; Yancey AM
Ther Adv Cardiovasc Dis; 2018 Aug; 12(8):207-216. PubMed ID: 29914293
[TBL] [Abstract][Full Text] [Related]
17. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
18. The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center.
Sacha GL; Greenlee KM; Ketz JM
J Thromb Thrombolysis; 2016 Nov; 42(4):479-85. PubMed ID: 27256341
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Deal EN; Hollands JM; Riney JN; Skrupky LP; Smith JR; Reichley RM
J Thromb Thrombolysis; 2011 Aug; 32(2):188-94. PubMed ID: 21465129
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
Gulati A; Faed JM; Isbister GK; Duffull SB
Pharm Res; 2012 Jan; 29(1):225-35. PubMed ID: 21822767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
